pAMPK positivity is associated with nuclear overexpression of pSMAD2 and SMAD4, through stimulation of TGF-β-independent phosphorylation of SMAD2, which is a novel antitumoral mechanism for pAMPK in ccRCC. The gene discussed is TGFB1; the disease is nonpapillary renal cell carcinoma.